BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN) today announced its financial results for the third quarter of 2006. For the three months ended September 30, 2006, Enzon reported net income of $2.2 million or $0.05 per diluted share, as compared to a net loss of $5.8 million or $(0.13) per diluted share.
